Suppr超能文献

人抗A类 Ephrin 受体 2 抗体片段与其同源抗原复合物的结晶及初步 X 射线衍射分析

Crystallization and preliminary X-ray diffraction analysis of the complex of a human anti-ephrin type-A receptor 2 antibody fragment and its cognate antigen.

作者信息

Oganesyan Vaheh, Damschroder Melissa M, Phipps Sandrina, Wilson Susan D, Cook Kimberly E, Wu Herren, Dall'Acqua William F

机构信息

Department of Antibody Discovery and Protein Engineering, MedImmune, One MedImmune Way, Gaithersburg, MD 20878, USA.

出版信息

Acta Crystallogr Sect F Struct Biol Cryst Commun. 2010 Jun 1;66(Pt 6):730-3. doi: 10.1107/S1744309110015861. Epub 2010 May 29.

Abstract

The recombinant N-terminal domain of human ephrin type-A receptor 2 (rEphA2) has been crystallized in complex with the recombinantly produced Fab fragment of a fully human antibody (1C1; IgG1/kappa). These are the first reported crystals of an ephrin receptor bound to an antibody. The orthorhombic crystals belonged to space group C222(1) (the 00l reflections obey the l = 2n rule), with unit-cell parameters a = 78.93, b = 120.79, c = 286.20 A. The diffraction of the crystals extended to 2.0 A resolution. However, only data to 2.55 A resolution were considered to be useful owing to spot overlap caused by the long unit-cell parameter. The asymmetric unit is most likely to contain two 1C1 Fab-rEphA2 complexes. This corresponds to a crystal volume per protein weight (V(M)) of 2.4 A(3) Da(-1) and a solvent content of 49.5%. The three-dimensional structure of this complex will shed light on the molecular basis of 1C1 specificity. This will also contribute to a better understanding of the mechanism of action of this antibody, the current evaluation of which as an antibody-drug conjugate in cancer therapy makes it a particularly interesting case study.

摘要

人 EphA2 型受体的重组 N 端结构域(rEphA2)已与一种全人源抗体(1C1;IgG1/kappa)的重组 Fab 片段形成复合物并结晶。这些是首次报道的 Ephrin 受体与抗体结合的晶体。正交晶体属于空间群 C222(1)(00l 反射服从 l = 2n 规则),晶胞参数 a = 78.93、b = 120.79、c = 286.20 Å。晶体的衍射延伸至 2.0 Å 分辨率。然而,由于长晶胞参数导致的斑点重叠,仅 2.55 Å 分辨率的数据被认为是有用的。不对称单元很可能包含两个 1C1 Fab-rEphA2 复合物。这对应于每蛋白质重量的晶体体积(V(M))为 2.4 ų Da⁻¹,溶剂含量为 49.5%。该复合物的三维结构将阐明 1C1 特异性的分子基础。这也将有助于更好地理解该抗体的作用机制,目前将其作为癌症治疗中的抗体药物偶联物进行评估,使其成为一个特别有趣的案例研究。

相似文献

5
Crystallization of BMP receptor type IA bound to the antibody Fab fragment AbD1556.与抗体Fab片段AbD1556结合的IA型骨形态发生蛋白受体的结晶。
Acta Crystallogr Sect F Struct Biol Cryst Commun. 2010 Aug 1;66(Pt 8):964-8. doi: 10.1107/S1744309110024681. Epub 2010 Jul 29.

本文引用的文献

5
Regulation of angiogenesis by Eph-ephrin interactions.Eph-ephrin相互作用对血管生成的调控。
Trends Cardiovasc Med. 2007 Jul;17(5):145-51. doi: 10.1016/j.tcm.2007.03.003.
7
Bidirectional ephrin/Eph signaling in synaptic functions.双向 Eph 受体配体/Eph 信号在突触功能中的作用
Brain Res. 2007 Dec 12;1184:72-80. doi: 10.1016/j.brainres.2006.11.033. Epub 2006 Dec 12.
9
The role of ephrins and Eph receptors in cancer.Ephrin 与 Eph 受体在癌症中的作用。
Cytokine Growth Factor Rev. 2004 Dec;15(6):419-33. doi: 10.1016/j.cytogfr.2004.09.002.

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验